Study ID: Lung-MAP
Lung-MAP is a master screening protocol for previously treated non-small cell lung cancer
This study for patients with recurrent non-small cell lung cancer is a randomized phase 2/phase 3 trial meant to establish a method for screening the genes of large populations of cancer patients and then assigning those patients, when appropriate, to a sub-study.
If assigned to a sub-study, participants will then undergo a new, targeted cancer therapy or a combination of standard care.
The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Lung-MAP contains a screening component and a clinical trial component:
- Patients can participate in the screening component either at progression on prior therapy or to be pre-screened while receiving therapy for stage IV or recurrent NSCLC.
- The clinical trial component consists of studies evaluating drug-biomarker combination for patients determined to have a matching biomarker, and non-match studies evaluating therapies in patients without any of the study biomarkers.
- Eligible patients must have been diagnosed with stage IV or recurrent NSCLC.
Patients must have received at least one line of systemic therapy for any stage of NSCLC and must have progressed during or after their most recent line of therapy.
The Lung-MAP sub-studies available at Main Line Health:
- 1800A is testing ramucirumab and pembrolizumab vs. standard of care in treating patients with stage IV or recurrent NSCLC.
- S1900A is a phase II study of rucaparib in patients with genomic LOH high and/or deleterious BRCA 1/2 mutation stage IV or recurrent NSCLC.
Contact the clinical trials team for additional details on sub-study eligibility.
- Must have been diagnosed with non-small cell lung cancer and previously undergone treatment